ALMR Alamar Biosciences, Inc.
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. It has a strategic partnership with Alzheimer's Disease Data Initiative, and Gates Ventures to advance translational research in alzheimer's disease. The company was incorporated in 2018 and is based in Fremont, California.…
Industry Peers
Medical DevicesKey Statistics
About Alamar Biosciences (NASDAQ: ALMR)
›
Alamar Biosciences (NASDAQ: ALMR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 308 employees.
The shares were at 28.68 USD on 19 November 2026. Its 52-week range is 18.84 USD to 39.61 USD: the price is 27.6% below the high and 52.2% above the low.
Its market capitalisation is 1.99B USD.
Alamar Biosciences reports return on equity of 18.8%, an operating margin of -42.1% and revenue up 68.5% year over year.
It holds more cash than debt, a net cash position of 184.23M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 5 analysts cover the stock; their mean price target of 37.00 USD is 29.0% above the current price. The next earnings report is expected on 18 February 2027.